Investor Presentation on Zoetis Exclusive Global License
Investor Presentation on Zoetis Exclusive Global License
Brisbane, May 16, 2018 AEST (ABN Newswire) - Anatara Lifesciences (ASX:ANR) is pleased to release a new investor presentation following the announcement that Anatara had established an exclusive licensing agreement with Zoetis Inc., the leading global animal health company, for the worldwide development, manufacture, distribution and marketing of Detach(R) as a non-antibiotic approach to aid in the control of diarrhoeal disease (known as scour) in livestock and in horses.

Key points:

- Anatara releases investor presentation containing structure and terms of its recently announced exclusive global license agreement for lead product, Detach(R) with Zoetis Inc., the leading global animal health company

The investor presentation includes additional information on the structure of the agreement, including the deal terms for up front payments and milestones, and the expected royalty range on product sales.

About Zoetis

Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2017, the company generated annual revenue of $5.3 billion with approximately 9,000 employees. For more information, visit www.zoetis.com.

To view the presentation, please visit:
http://abnnewswire.net/lnk/N411A524


About Anatara Lifesciences Ltd

Anatara Lifesciences ASX ANRAnatara Lifesciences (ASX:ANR) is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach(R) is a natural plant based product that aids in the control of diarrhoea and will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called "super bugs" that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.

    


Contact

General inquiries:
Investor Relations - Anatara Lifesciences
Phone: +61-7-3394-8202
Email: info@anatara.com

Media inquiries:
Jane Lowe
Managing Director, IR Department
Phone: +61-411-117-774
Email: jane.lowe@irdepartment.com.au



Related Companies

Anatara Lifesciences Ltd

ABN Newswire This Page Viewed:  (Last 7 Days: 48) (Last 30 Days: 213) (Since Published: 1490) 
ANALYTICS: LOGIN HERE

Anatara Lifesciences Ltd NEWS: RECENT VISITS (3510)

Research Report

Social Media